Jan. 2, 2024—Roche announced it has entered into a definitive agreement to acquire LumiraDx’s point-of-care technology platform business, which offers a range of immunoassay and clinical chemistry tests that can be stored at room temperature. Roche will pay a purchase price of $295 million and an additional payment of up to $55 million for the reimbursement of amounts to fund the POC technology platform business until the closing of the acquisition.
“The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care,” Matt Sause, CEO of Roche Diagnostics, said in a press release. “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralized health care settings worldwide.”
Following closing of the transaction, which is expected by midyear, the acquired entities will be fully integrated into Roche Diagnostics. The transaction is subject to certain conditions including antitrust and regulatory approvals.